EUVIMEDEUVIMED entdecken
Crossref

Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis

Rahul S Dalal iD, Lindsay M Clarke, Alex Carlin, Heidy Cabral, Jessica R Allegretti iD

Inflammatory Bowel Diseases · 10.04.2025 · 31 (4) · 1174-1177

DOI: 10.1093/ibd/izae215 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 19.09.2024. Verfasst von Rahul S Dalal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Brigham and Women's Hospital Faculty Career Development Award, Brigham and Women’s Hospital Faculty Career Development Award.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lay Summary In this retrospective cohort study, vedolizumab was associated with higher odds of steroid-free clinical remission at 1 year compared to anti-TNF agents for bio-naïve patients with ulcerative proctitis.

Schlagwörter

Stichwörter der Autor:innen

bio-naïvebiologicsinflammatory bowel diseaseulcerative colitis

Autor:innen und Institutionen

  • Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

ORCID-Profile: Rahul S Dalal, Jessica R Allegretti

Förderung

  • Brigham and Women's Hospital Faculty Career Development Award
  • Brigham and Women’s Hospital Faculty Career Development Award

Zitieren

APA

Dalal, R. S., Clarke, L. M., Carlin, A., Cabral, H., & Allegretti, J. R. (2025). Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis. Inflammatory Bowel Diseases, 31(4), 1174-1177. https://doi.org/10.1093/ibd/izae215

Vancouver

Dalal RS, Clarke LM, Carlin A, Cabral H, Allegretti JR. Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis. Inflammatory Bowel Diseases. 2025;31(4):1174-1177. doi:10.1093/ibd/izae215

BibTeX
@article{Dalal2025,
  author = {Dalal, Rahul S and Clarke, Lindsay M and Carlin, Alex and Cabral, Heidy and Allegretti, Jessica R},
  title = {Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {4},
  pages = {1174--1177},
  doi = {10.1093/ibd/izae215}
}
Kostenlos starten →